



Empowering You to Live with Confidence



Expanding the Possibilities of a Better Tomorrow



So You Can Share More Time with Those You Love



ABOUT COMPANY



The Value of Life Sciences—Adding, Multiplying, and Sharing

Vision		03
What EHL Does		08
Stem Cells		09
Immune Cells		11
Stem Cell-Conditioned Medium		13
Philosophy		15
Mission		16
History		17
Directions		30

E

**Aesthetics is about adding confidence to life.**

EHLBIO goes beyond outward beauty to explore the moments when confidence and dignity are restored.

H

**Health is about multiplying possibilities.**


We help healthy cells, healthy recovery, and healthy daily living expand the possibilities of life.

L

**Longevity is about sharing more time.**

It is not simply about living longer, but about creating more time to laugh and be together with the people we love.





See the Future at EHL!

Today, EHL continues its dynamic rise as a biotechnology company attracting worldwide attention.


EHL BIO is a research and development institute established to extend human longevity and help people lead younger, healthier lives by developing solutions to overcome disease and aging.

We are leading the commercialization of innovative treatments by combining the development of stem cell and immune cell therapies—key areas of future regenerative medicine—with groundbreaking medical cell therapy technologies.

The EHL BIO Research Institute is dedicated to research and development in regenerative medicine for the treatment of neurological, osteoarticular, cardiovascular, metabolic, and autoimmune diseases, as well as anti-aging, health promotion, hair-loss treatment, and aesthetic dermatology.







Life Science That Creates Tomorrow

**With limitless ideas and infinite possibilities,
we create the driving force of an unstoppable tomorrow.**

For EHL BIO, the future is not something to wait for—it is something we create.

So that life's brightest moments may stay with us longer...

With limitless ideas and infinite possibilities,
we will protect you from fear.





EHL Protects You.

Personalized medical care cannot be easily replicated. It requires the knowledge, technology, and expertise gained through years of bringing cell therapies into clinical practice. A personalized solution designed for your body begins with your own cells.



Regenerative Medicine (Regenerative Medicine)

Regenerating damaged tissues and organs

- 1 Adipose-Derived Stem Cells** | World's First Phase III IV Trial
 - Stem cell therapy for diseases caused by impaired organ or tissue function (liver cirrhosis, diabetes, hypertension, Parkinson's disease, rheumatoid arthritis, and other intractable diseases)
 - Anti-aging treatment
- 2 Urine-Derived Stem Cells (KLOCELL)** | World-First Trial
 - Demonstrates superior efficacy in treating kidney, urinary, and reproductive system disorders compared with other stem cells
 - First in the world to demonstrate that UDSCs are stem cells that secrete Klotho (Published in an international journal / Patent granted)
 - World's first KLOCELL clinical trial for chronic diseases planned
- 3 EPC (Vascular Endothelial Cells)**
 - Cells designed to restore damaged vascular endothelial function and promote blood vessel regeneration
 - Used to improve microcirculation and support recovery through angiogenesis

Defensive Medicine (Defensive Medicine)

Protection against cancer and viruses

- 1 N.K**
 - Representative immune cells of the first line of defense (innate immunity), capable of recognizing abnormal cells and immediately detecting and eliminating cancer cells, virus-infected cells, and other abnormal cells
- 2 D.C**
 - Professional antigen-presenting cells involved in both innate and adaptive immunity, primarily presenting antigens to T cells
- 3 T**
 - Cells that express T-cell receptors (TCRs) capable of recognizing specific antigens on cancer cells and virus-infected cells

Anti-Aging Medicine (Anti-aging Medicine)

Healthy longevity and anti-aging medicine

- 1 KLOSOME®** (Method-of-Use Patent / Composition-of-Matter Patent / Trademark Registration)
 - Anti-aging effects of Klotho protein
 - Skin-regenerative efficacy of stem cell-derived exosomes


Stem Cells

What Are Stem Cells?


Stem cells are undifferentiated cells with the ability to self-renew and differentiate into approximately 210 types of specialized cells that make up the human body.

Characteristics of Stem Cells


- **Self-Renewal** : Stem cells can produce new stem cells with the same form and capabilities as themselves.
- **Differentiation** : Stem cells can transform from an undifferentiated state into specialized cells with specific structures and functions according to the body's needs.
- **Homing Effect** : When administered intravenously, stem cells can migrate to damaged areas of the body.



Self-Renewal




Differentiation
Capacity




Homing Effect

Functions of Stem Cells


- **Wound Healing** : Regenerates damaged cells
- **Differentiation** : Differentiates into damaged cell types and regenerates healthy cells
- **Paracrine Effect** : Improves tissues by secreting cytokines and growth factors
- **Immune Regulation** : Regulates immunity by normalizing the function of immune-related organs
- **Prevention of Cell Death** : Helps prevent cell death in the body
- **Blood Supply Through Angiogenesis** : Regenerates damaged blood vessels and supports normal blood flow




Wound Healing




Differentiation




Paracrine Effect




Immune Regulation



Prevention of
Cell Death



Blood Supply Through
Angiogenesis



Immune Cells


What Are Immune Cells?

Immune cells protect the body from external threats such as pathogens and viruses, as well as abnormal cells within the body, including cancer cells.

Immunity

Immunity is the body's defense against foreign substances and abnormal self-derived materials. A properly functioning immune system eliminates foreign substances, cancer cells, and cellular waste to maintain health. However, insufficient immune activity can lead to chronic infections and cancer, while excessive immune activity may cause allergies or autoimmune diseases.


Immune cells include macrophages and NK cells involved in innate immunity; T cells and B cells involved in adaptive immunity; and dendritic cells and gamma delta T cells involved in both immune responses.




Attacks virus-infected cells and tumor cells




- Phagocytosis and bactericidal activity
- Removal of foreign substances and cellular waste
- Antigen presentation and antiviral activity
- Anticancer activity




The most potent antigen-presenting cells against cancer cells



Antibody production



Immune Regulation and Enhancement in Various Immune Disorders



Attacks Tumor Cells Through MHC Binding

EHL Protects You from Cancer and Disease.

We share the same dream.


For a healthier life, EHL will be with you.



Stem Cell-Conditioned Medium

What Is Stem Cell-Conditioned Medium?

Stem cell-conditioned medium is a culture-derived material produced during the cultivation and proliferation of stem cells. It contains various components beneficial to human skin, including growth factors, cytokines, fibronectin, and collagen, and is gaining attention as a premium cosmetic ingredient.



EHL Promises a Different Tomorrow.

Layer by layer, discover renewed skin.

The magic of growth factors in stem cell-conditioned medium
promises a brighter tomorrow.



Philosophy

Our Promise: A 200-Year Company

EHL aspires to become a company that endures for 200 years and serves as the salt of the earth. Through communication and collaboration, autonomy and responsibility, and professional expertise, we create the future and stand by you through every moment.




SALT UP

Mission

Building the Infrastructure for a 200-Year Company

Biotechnology is transforming not only everyday life but also the pharmaceutical and healthcare industries. EHL will analyze existing businesses, identify promising future opportunities, and build bio-industry infrastructure to drive new growth in pharmaceuticals and healthcare.



History

We Look Forward to Every New Morning.

Since taking its first step as a biotechnology company in 2012, EHL has continued to grow, embracing change every morning.

The excitement of transformation inspires us to look forward to tomorrow.

2012

A Great First Step

- Established EHL Bio Co., Ltd.
- Certified as a Corporate Research Institute by the Korea Industrial Technology Association (KOITA)

2016

Proving Our Capabilities

- ADSTEM® received approval for the world's first Phase I clinical trial (Autologous adipose-derived stem cells / Intravenous administration / Atopic dermatitis)
- Awarded a Startup Growth Technology Development Project by the Ministry of SMEs and Startups

2019

Leading the Market

- Completed the K2 GMP Center with a total production capacity of 6,600 batches
- ADSTEM® received Phase II clinical trial approval (Autologous adipose-derived stem cells / Intravenous administration / Atopic dermatitis)
- Secured a contract manufacturing organization (CMO) agreement for clinical investigational products
- Secured a contract development and manufacturing organization (CDMO) agreement for a clinical cell bank

2015

Gaining Confidence

- Certified as a Venture Company by the Korea Technology Finance Corporation (KIBO)
- Completed the K1 GMP Center with a total production capacity of 4,000 batches

2017

Expanding Globally

- Received approval from Japan's Ministry of Health, Labour and Welfare for a Cell Processing Center (CPC)
- Established an overseas subsidiary in Hanoi, Vietnam
- Completed the ADSTEM® Phase I clinical trial

2021

Bold Execution

- Obtained Korea's first license from the Ministry of Food and Drug Safety for the management of human cells and related materials
- Obtained Korea's first license from the Ministry of Food and Drug Safety for a cell processing facility
- Achieved ISO 9001:2015 Quality Management System certification

2022

A Memorable 10th Anniversary

- Awarded a Pan-Ministerial Regenerative Medicine Technology Development Project by the Ministry of Science and ICT and the Ministry of Health and Welfare [Total Research Funding: KRW 1.17 Billion]

2024

From Innovation to the Standard

- Awarded a Pan-Ministerial Regenerative Medicine Technology Development Project by the Ministry of Science and ICT and the Ministry of Health and Welfare [Total Research Funding: KRW 2.57 Billion]
- Received the Minister of Health and Welfare Commendation for Contributions to the Advancement of Regenerative Medicine
- Selected Top 10 Project in Pan-Ministerial Regenerative Medicine Program
- Completed the E GMP Center with a total production capacity of 10,800 batches
- Submitted a Phase III clinical trial application for ADSTEM®
- KDSTEM® approved for advanced regenerative medicine clinical study (Autologous KLOCELL / IV / Diabetic kidney disease)

2026

Completing the Foundation of Trust

- Awarded a 2026 Pan-Ministerial Regenerative Medicine Technology Development Project
- Completed the Phase I clinical trial of KDSTEM
- Selected as an Outstanding Corporate Research Institute by the Ministry of Science and ICT

2023

A Great First Step

- KDSTEM® received approval for the world's first Phase I clinical trial (Autologous KLOCELL / Intravenous administration / Chronic kidney disease)
- Completed the ADSTEM® Phase II clinical trial (Autologous adipose-derived stem cells / Intravenous administration / Atopic dermatitis)
- Established an overseas subsidiary in Jakarta, Indonesia

2025

World-Class Biotechnology

- Completed the Nagoya CPC and Cell Center in Japan
- Received Phase III clinical trial approval for ADSTEM Injection
- Established a CPC in Vietnam
- Obtained Inno-Biz certification as a Technology-Innovative SME
- Received the 10th IR52 Jang Young-sil Technology Innovation Award
- Obtained MAIN-Biz certification as a Management-Innovative SME
- Obtained ISO 14001, ISO 45001, ISO 27001, and ISO 37301 certifications

Precision technology beyond the visible— we pay attention to every detail.

Cell-handling outcomes vary according to individual expertise and teamwork. EHL operates through a central control tower, closely monitoring even the slightest changes.

Our greatest strength is enabling every team member to perform at their best in perfect harmony.





Strengths

Synergy Between Medicine and Biotechnology


Where medicine meets science, physicians' dedication and understanding of customers' needs enable us to design a healthier future.

At EHL, physicians and scientists collaborate on shared research objectives while conducting research and clinical practice in parallel, giving us an advantage in both quality and speed. Experience advanced medical services at EHL, where a specialized cell therapy hospital and research institute operate together.



Strengths

A Diverse Cell Therapy Pipeline



Atopic Dermatitis Treatment (ADSTEM) : Phase III clinical trial underway in 2026

Kidney Failure Treatment (KDSTEM) : Expected to enter Phase II clinical trials in 2027

Pulmonary Fibrosis Treatment (Macrophages) : Entering the preclinical stage in 2026

Angina Treatment (EPC) : EPC-based therapy entering preclinical stage in 2026

To extend the human lifespan to 150 years and support healthier lives, stem cell and immune cell therapies, along with the early detection of genetic abnormalities, are essential.

EHL is a leading company supplying a broad range of stem cells and immune cells tailored to customer needs.

Experience safe and comfortable cell therapy at EHL.

Lung Cancer Treatment (NK, DC, and T Cells) : Introduced into regenerative medicine in 2025

Clinical trials are studies conducted in humans to evaluate the safety and efficacy of new drugs or treatments.

Following preclinical studies, in which safety and efficacy are assessed through animal testing, clinical development proceeds through Phase I (safety), Phase II (efficacy and dosage), Phase III (large-scale confirmation of safety and efficacy), and Phase IV (post-marketing surveillance and additional evaluation). This process requires considerable time and investment.

Among these stages, Phase III is the most critical, as it provides the final confirmation of a treatment's efficacy and safety and may lead to conditional marketing authorization. EHL BIO is developing an adipose-derived stem cell therapy for atopic dermatitis and is a biotechnology company with unrivaled technological expertise, conducting the world's first Phase III clinical trial in this field.


Through disease-targeted cell therapies for a wide range of conditions, EHL BIO is leading the way into a new era of personalized cell therapy.

Strengths

World-Class GMP Facilities and Optimized Operational Expertise

Good Manufacturing Practices (GMP) are the standards required by regulatory authorities for the manufacture and sale of pharmaceutical products.

EHL operates GMP-compliant facilities and completed its third GMP facility in 2024 in accordance with global standards, establishing the capacity to culture approximately 24,000 lots of cells annually.



Strengths

Patent Applications and Registrations Through Continuous Research




EHL aims to become a world-leading research-driven biotechnology company by playing a pivotal role in advancing national science and technology in the field of novel drug development. To achieve this, we continue to expand our advanced research infrastructure, recruit top talent, publish outstanding research achievements, and pursue patent applications and registrations for innovative technologies.

Korean Patents	Novel Thiazolidinedione Derivatives and Uses Thereof	2012.08.02	10-2011-7017782
	Adipose Tissue Collection and SVF Isolation Kit	2016.01.20	10-2016-0007049
	Composition Comprising Cells Treated with a 15-PGDH Inhibitor or a Culture Thereof, and Uses Thereof	2016.10.26	10-2016-0139967
	Composition Comprising Cells Treated with a 15-PGDH Inhibitor or a Culture Thereof, and Uses Thereof	2018.01.04	10-2018-0001149
	Cosmetic Composition Containing Stem Cell-Conditioned Medium and Method for Preparing the Stem Cell-Conditioned Medium	2018.03.16	10-2018-0030906
	Method for Differentiating Tonsil-Derived Mesenchymal Stem Cells into Motor Neurons	2019.03.26	10-2019-0034176
	Culture Medium Composition for Urine-Derived Stem Cells and Method for Culturing Urine-Derived Stem Cells Using the Same	2019.11.04	10-2019-0139702
	Method for Large-Scale Culture of Adipose-Derived Stem Cells Expressing Anti-Aging Factors	2020.02.03	10-2020-0012437
	Composition Containing Stem Cell-Derived Exosomes as an Active Ingredient for Skin Regeneration, Whitening, Antioxidation, or Wound Treatment, and Uses Thereof	2021.02.17	10-2021-0021026
	Culture Medium and Methods for Urine-Derived Stem Cells with Enhanced Kidney Disease Therapeutic Potential	2021.09.29	10-2021-0129299
	Urine-Neutralizing Composition for Preserving Cells in Urine and Method for Neutralizing Urine Using the Same	2024.01.23	10-2024-0010025
	Adipose-Derived Stem Cells with Enhanced Responsiveness in Secreting Immunomodulatory Factors, Method for Producing the Same, and Uses Thereof	2025.01.16	10-2025-0006588
International Patents	Composition Containing Stem Cell-Derived Exosomes for Skin Regeneration, Whitening, Antioxidation, or Wound Treatment	2022.02.07	PCT/KR2022/001851
	Culture Medium and Methods for Urine-Derived Stem Cells with Enhanced Kidney Disease Therapeutic Potential	2021.04.19	PCT/KR2022/005579

Strengths

First Approval as a Human Cell Management Business and Cell Processing Facility, Approval by Japan's Ministry of Health, Labour and Welfare, and Recipient of the Jang Young-sil Award

Under the Advanced Regenerative Medicine and Advanced Biopharmaceuticals Act, a new era of stem cell and immune cell therapy has begun in Korea. A Human Cell Management Business is a licensed facility that supplies raw materials to advanced biopharmaceutical companies. EHL became the first company in Korea to receive approval from the Ministry of Food and Drug Safety. EHL BIO's outstanding technology has also gained significant attention as the first cell therapy company to receive the Jang Young-sil Technology Innovation Award.



- Proprietary cell culture expertise and patents
- Proprietary cell expansion technology
- Superior stem cell yield and activity compared with competitors
- Over 1,000-fold higher stem cell recovery rate
- Minimal loss of viability before and after cryopreservation (Currently conducting Korea's first clinical trial involving repeated intravenous administration)



Competitive Research Network

EHL has established partnerships and maintains active collaboration with a diverse network of domestic and international organizations that share our commitment to advancing the future value of life science.

By sharing knowledge and professional expertise, we fulfill our role as a biotechnology company leading the industry.

Clinical Trial Sites	Seoul National University Hospital, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Korea University Ansan Hospital, Kyung Hee University Hospital, Chung-Ang University Hospital, and Chungnam National University Hospital
MOU Partner Hospitals	Chungnam National University Hospital, Dankook University Hospital, Chonnam National University Hospital, Chonnam National University Hwasun Hospital, Gangnam Severance Hospital, Wonkwang University Hospital, Seoul Songdo Hospital, and Madisarang Hospital
Partner Hospitals	Japan Century Clinic, An Viet Hospital in Vietnam, and over 50 other institutions
Collaborative Research	Kyoto University



Strengths

Development and Supply of Stem Cell and Immune Cell Culture Media

Culture Medium Development

EHL SC Medium


- EHL is developing its own optimized culture medium in line with the growing trend toward serum-free or reduced use of animal-derived serum. We are identifying factors that promote cell proliferation comparable to MesenPRO, a commercially available medium specifically designed for adipose-derived stem cells.




- Developing and commercializing a cost-competitive medium with performance comparable to expensive imported products, enabling high-quality cell therapy at lower treatment costs
- Efficacy and reproducibility validated through performance testing and blind testing; patent pending
- Prototype production of the newly developed culture medium is underway

- Dedicated Medium Optimized for UDSC Culture | Superior Proliferative Capacity and Stemness of EHL-UDSC

Cell Proliferation Rate (%)



Stem Cell Gene Expression



Strengths


Culture Media · Conditioned Media · Exosomes World's First Kidney-Derived Exosomes (KLOSOME)

Customized cosmetics made with undiluted stem cell conditioned media are effective in skin brightening, wrinkle improvement, and skin barrier protection. Developed through continuous biotechnology research, stem cell conditioned media contains abundant growth factors that help promote collagen production and anti-aging effects.

In particular, KLOSOME, a kidney-derived exosome containing the longevity protein Klotho, has been successfully commercialized using EHL BIO's proprietary technology and is currently undergoing joint clinical research with Kyoto University in Japan.

Premium Exosomes

- Exosomes are nanoscale vesicles secreted by all cells for intercellular communication and contain various bioactive substances. In particular, stem cell-derived exosomes are known as key substances that transmit the therapeutic effects of stem cells, including their differentiation and regenerative capabilities, and are used in the treatment of various conditions, including skin regeneration.




Composition Containing Stem Cell-Derived Exosomes as an Active Ingredient for Skin Regeneration, Skin Brightening, Antioxidation, or Wound Treatment, and Uses Thereof
Patent Registered (No. 10-2341375)


KLOSOME®

- KLOSOME is a premium exosome containing a longevity protein that extends cellular lifespan and protects cells from various types of stress.

■ KLOSOME® Human Skin Cell Proliferation Efficacy Evaluation




■ KLOSOME® Wound Regeneration Efficacy Evaluation



Those who have
experienced illness know
how joyful and precious
everyday life can be.

EHL Bio
Protects You.





EHL Cell Center

136 Apgujeong-ro, Gangnam-gu, Seoul, EHL Building
 440 m from Exit 5 of Apgujeong Station
 TEL 02-532-9855 | FAX 02-514-8027



Head Office & Research Institute

Rooms 411-412, Building B, Indeogwon IT Valley,
 40 Imi-ro, Uiwang-si, Gyeonggi-do
 Near Indeogwon Station, Subway Line 4
 TEL 02-535-9883-4
 FAX 070-4009-6979



www.ehlbio.co.kr

The Value of Life Sciences—
Adding, Multiplying, and Sharing
EHL Bio